2011
Differential Clinical Responses to Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients With and Without Diabetes Mellitus
Stone G, Kedhi E, Kereiakes D, Parise H, Fahy M, Serruys P, Smits P. Differential Clinical Responses to Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients With and Without Diabetes Mellitus. Circulation 2011, 124: 893-900. PMID: 21824922, DOI: 10.1161/circulationaha.111.031070.Peer-Reviewed Original ResearchConceptsPaclitaxel-eluting stentsPercutaneous coronary interventionEverolimus-eluting stentsDiabetes mellitusLesion revascularizationCoronary interventionStent thrombosisMyocardial infarctionStent typeIschemia-driven target lesion revascularizationEnd pointDifferential clinical responseXIENCE V EverolimusEfficacy end pointTarget lesion revascularizationTreatment of patientsCoronary stent systemSignificant differencesEverolimus-ElutingCoronary revascularizationEfficacy outcomesClinical responseDiabetic statusDiabetic patientsClinical outcomes
2005
Metabolic Syndrome as a Precursor of Cardiovascular Disease and Type 2 Diabetes Mellitus
Wilson P, D’Agostino R, Parise H, Sullivan L, Meigs J. Metabolic Syndrome as a Precursor of Cardiovascular Disease and Type 2 Diabetes Mellitus. Circulation 2005, 112: 3066-3072. PMID: 16275870, DOI: 10.1161/circulationaha.105.539528.Peer-Reviewed Original ResearchConceptsCoronary heart diseaseMetabolic syndromeCardiovascular diseaseRelative riskAge-adjusted relative riskType 2 diabetes mellitusPopulation attributable risk estimatesNew cardiovascular diseaseMetabolic syndrome traitsMiddle-aged adultsDiabetes mellitusIncident casesHeart diseaseNew T2DMT2DMType 2SyndromeEvent ratesRisk estimatesDiseaseSyndrome traitsMellitusWomenMenRisk